Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Diabetic Retinopathy

Clinical Trial Details

Overview

Research Study Summary

Patients are needed to participate in a clinical research study evaluating Lucentis (ranibizumab) for the treatment of Proliferative Diabetic Retinopathy

Research Study Title

Evaluation of Ranibizumab on the Ease of Procedure and Complication Rate in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Purpose

Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.

To Learn more
Phase

3

Gender

Both Male and Female

Age

21 and up

Overall Status

Recruiting

Lead Sponsor

Retina Associates, Kansas City

Facility Type

N/A

Eligibility

Both Male and Female ages 21 Years and up

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study

  • Age > 20 years

  • Best corrected visual acuity of 20/40 to 20/800 in the study eye

  • Very servere nonproliferative diabetic retinopathy (ETDRS level 53E) OR moderate proliferative diabetic retinopathy (ETDRS level 65)

  • Visual reduction attributable to diabetic vitreous hemorrhage or diabetic macular edema

  • Candidate for vitrectomy procedure

Exclusion Criteria:

  • Pregnancy (positive Pregnancy test) or lactation

  • Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.

  • Participation in another simultaneous medical investigation or trial.

  • Visual impairment attributable to causes other than diabetic macular edema or diabetic vitreous hemorrhage.

  • Use of intraocular or periocular corticosteroids within 6 months.

  • History of panretinal photocoagulation

  • History of macular laser photocoagulation

  • History of pars plana vitrectomy

  • Prior or concomitant treatment with ranibizumab, bevacizumab, or pegaptanib sodium, either as part of an investigational study or as an off-label medication.

  • Current treatment of a systemic infection

Site Locations (1)

Country State City Zip Facility and Contact
United States Kansas Shawnee Mission 66204 Retina Associates, PA
Lexie Manning
913-831-7400
lmanning@kcretina.com

Gregory M Fox, MD
Principal Investigator

NCT ID: NCT00516464

Date Last Changed: August 14, 2007

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.